![]() |
|
|
DW Bonhaus, DN Loury, LB Jakeman, Z To, A DeSouza, RM Eglen and EH Wong
Department of Neurosciences, Syntex Discovery Research, Palo Alto, California.
The binding of [3H]endo-N-(8-methyl-8-azabicyclo[3.2.1.]oct-3-yl)- 2,3- dihydro-3-ethyl-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride ([3H]BIMU-1) a benzimidazolone with high affinity for 5- hydroxytryptamine (5-HT)3 and 4 5-HT3 and 5-HT4 receptors, was characterized in NG-108 cells and guinea pig hippocampus. Specific, heat-sensitive, binding of [3H]BIMU-1 was detected in both NG-108 cells and guinea pig hippocampus. In NG-108 cell membranes, a portion of the specific binding was displaced by 5-HT3 receptor ligands with affinities and specificity consistent with the labeling of 5-HT3 receptors. The residual specific binding was insensitive to serotonin (Ki > 1 mM) but was displaced by haloperidol (Ki of 50 nM). In guinea pig hippocampal membranes [3H]BIMU-1 binding was insensitive to serotonin but was displaced by haloperidol, and 1,3-di-o-tolyl- guanidine with affinities appropriate for the labeling of a sigma binding site (Ki of 6.3 and 31 nM, respectively). The affinity profile of ligands displacing [3H] BIMU-1 binding in guinea pig hippocampus was consistent with the selective labeling of a sigma-2 binding site because the sigma-1 selective benzomorphans, (+)-pentazocine and (+)-N- allylnormetazocine, only weakly displaced the binding (Ki greater than 1 microM). The affinity of BIMU-1 for sigma-2 binding sites (Ki = 32 nM) was 200-fold greater than that for sigma-1 binding sites (Ki = 6.3 microM), dopamine (D1 and D2), other serotonin (5-HT1A, 5-HT2A, 5-HT2C) and muscarinic (M1, M2, M3 and M4) receptors (Ki > 10 microM). The distribution of haloperidol-sensitive [3H]BIMU-1 binding was also consistent with the labeling of sigma-2 binding sites. These data suggest that [3H]BIMU-1 selectively labels sigma-2 binding sites in guinea pig hippocampus. [3H]BIMU-1, under appropriate experimental conditions, is thus the first sigma-2 binding site radioligand to be characterized.
This article has been cited by other articles:
![]() |
A. Papageorgiou and C. Denef Stimulation of Growth Hormone Release by 5-Hydroxytryptamine (5-HT) in Cultured Rat Anterior Pituitary Cell Aggregates: Evidence for Mediation by 5-HT2B, 5-HT7, 5-HT1B, and Ketanserin-Sensitive Receptors Endocrinology, September 1, 2007; 148(9): 4509 - 4522. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Papageorgiou and C. Denef Estradiol Induces Expression of 5-Hydroxytryptamine (5-HT) 4, 5-HT5, and 5-HT6 Receptor Messenger Ribonucleic Acid in Rat Anterior Pituitary Cell Aggregates and Allows Prolactin Release via the 5-HT4 Receptor Endocrinology, March 1, 2007; 148(3): 1384 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Derbez, R. M. Mody, and L. L. Werling sigma 2-Receptor Regulation of Dopamine Transporter via Activation of Protein Kinase C J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 306 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Weatherspoon and L. L. Werling Modulation of Amphetamine-Stimulated [3H]Dopamine Release from Rat Pheochromocytoma (PC12) Cells by sigma Type 2 Receptors J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 278 - 284. [Abstract] [Full Text] |
||||
![]() |
N. Galeotti, C. Ghelardini, and A. Bartolini Role of 5-HT4 Receptors in the Mouse Passive Avoidance Test J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1115 - 1121. [Abstract] [Full Text] |
||||
![]() |
D. T. Ault, J. M. Radeff, and L. L. Werling Modulation of [3H]Dopamine Release from Rat Nucleus Accumbens by Neuropeptide Y May Involve a Sigma1-like Receptor J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 553 - 560. [Abstract] [Full Text] |
||||